This study examines whether the serine/threonine protein kinase, Akt, is involved in the crosstalk between the ErbB2 and estrogen receptor-a (ER-a) pathways. Treatment of MCF-7 cells with 10 À9 m heregulin-b1 (HRG-b1) resulted in a rapid phosphorylation of Akt and a 15-fold increase in Akt activity. Akt phosphorylation was blocked by inhibitors of phosphatidylinositol 3-kinase (PI 3-K), by antiestrogens, the protein tyrosine kinase inhibitor, genistein, and by AG825, a selective ErbB2 inhibitor; but not by AG30, a selective EGFR inhibitor. Akt phosphorylation by HRG-b1 was abrogated by an arginine to cysteine mutation (R25C) in the pleckstrin homology (PH) domain of Akt, and HRG-b1 did not induce Akt phosphorylation in the ER-negative variant of MCF-7, MCF-7/ADR. Transient transfection of ER-a into these cells restored Akt phosphorylation by HRG-b1, suggesting the requirement of ER-a. HRG-b1 did not activate Akt in MCF-7 cells stably transfected with an anti-ErbB2-targeted ribozyme, further confirming a role for ErbB2. Stable transfection of the cells with a dominant negative Akt or with the R25C-Akt mutant, as well as PI 3-K inhibitors, blocked the effect of HRG-b1 on ER-a expression and activity and on the growth of MCF-7 cells. Stable transfection of MCF-7 cells with a constitutively active Akt mimicked the effect of HRG-b1. Experiments employing selective ErbB inhibitors demonstrate that the effect of HRG-b1 on ER-a expression and activity is also mediated by ErbB2 and not by EGFR, demonstrating that ErbB2 is the primary mediator of the effects of HRG-b1 on ER-a regulation. Taken together, our data suggest that HRG-b1, bound to the ErbB2 ErbB3 heterodimer, in the presence of membrane ER-a, interacts with and activates PI 3-K/Akt. Akt leads to nuclear ER-a phosphorylation, thereby altering its expression and transcriptional activity.
Introduction
More than 60% of human breast cancers express estrogen receptor (ER) and hormone therapy is one of the most common treatments for breast cancer patients. The expression of ER is used to predict which patients will respond to hormone therapy. However, not all patients with positive ER will benefit from endocrine therapy (Houston et al., 1999) . It is being recognized increasingly that a variety of growth factors, their receptors, and their signaling pathways interact with ER signaling to suppress or stimulate the growth of ERpositive breast cancers. Also, alterations in ER and growth factor receptors occur in human cancers.
The ER belongs to a superfamily of ligand-inducible transcription factors (Weigel, 1996) . In the absence of hormone, the inactive receptor is complexed with a host of proteins, including heat-shock proteins, which prevent it from interacting with the cellular transcription apparatus. Upon estrogen binding, the receptor undergoes a conformational change that permits it to bind to coactivators and initiate the transcription of target genes. Activation of ER is also associated with an increase in phosphorylation (Orti et al., 1992) , and ER is known to act not only as a steroid hormone nuclear receptor but also as a cell-surface receptor linked to several intracellular pathways, such as the mitogen activator protein kinase (MAPK) (Razandi et al., 1999; Menard et al., 2000) or the PI 3-K/Akt (Martin et al., 2000; Simoncini et al., 2000; Campbell et al., 2001) pathways.
The ErbB family of receptor tyrosine kinases has four known members: ErbB1 (EGFR), ErbB2, ErbB3, and ErbB4 (Ullrich et al., 1984; Yamamoto et al., 1986; Kraus et al., 1989; Plowman et al., 1993) . They are widely expressed in epithelial, mesenchymal, and neuronal tissues and play fundamental roles during development. They have been implicated in the regulation of a variety of biological processes including cell proliferation, apoptosis, and differentiation (Tzahar and Yarden, 1998) . Unlike the other family members (EGFR, ErbB3, and ErbB4) , no ligand has yet been identified for ErbB2. However, ErbB2 can be activated by its own overexpression (Pierce et al., 1991) or be transactivated by heregulins (HRG) (Holmes et al., 1992; Lupu et al., 1992; Peles et al., 1992) . HRGs, also called neu differentiation factors or neuregulins, are a family of polypeptide growth factors derived from alternatively spliced genes (Holmes et al., 1992; Falls et al., 1993) . They exert their function by binding to ErbB3 or ErbB4, thereby inducing heterodimerization with ErbB2, and leading to receptor tyrosine phosphorylation and activation of downstream signal transduction (King et al., 1988; Plowman et al., 1993; Carraway and Cantley, 1994; Sliwkowski et al., 1994) . The ErbB receptor tyrosine kinases are overexpressed in two-thirds of human breast cancers and are associated with malignant transformation (Slamon et al., 1987 (Slamon et al., , 1989 Gullick, 1991; Harris et al., 1992; Dougall et al., 1994; Hynes and Stern, 1994) . ErbB2 is overexpressed in about 30% of human breast cancer patients and correlates with a poor prognosis (Slamon et al., 1987; De Potter et al., 1990; Paik et al., 1990; Allred et al., 1992; Gusterson et al., 1992 ). The precise mechanism by which ErbB receptors are involved in human cancer progression remains poorly understood, but, presumably, it involves signal transduction pathways that are activated by ligand binding (Tan et al., 1999) .
Crosscoupling between ErbB and ER signaling pathways has been reported in rodent uterine tissues (IgnarTrowbridge et al., 1992) and is reminiscent of the cooperativity between the viral erbA and erbB oncogenes in the malignant transformation of avian hematopoietic cells (Benchaibi et al., 1989) . In breast cancer, an inverse relation between ER and EGFR is quite clear. However, the relation between ER and other ErbB family members remains uncertain. Although a number of clinical studies found a correlation between hormone receptor status and ErbB2 amplification and overexpression, an equivalent number did not (Tauchi et al., 1989; Gullick, 1990; Lupu et al., 1993; Nicholson et al., 1993; Quenel et al., 1995) . Some studies have found that ErbB2 expression identifies certain subsets of patients, such as patients with ER-negative tumors, with increased risk of death (Berns et al., 1992; Tsusui et al., 2002) ; patients with ER-positive tumors likely to be resistant to chemotherapy (Allred et al., 1992) ; or patients failing to respond to endocrine therapy on relapse (Wright et al., 1992) . Some in vitro studies have reported that estrogen treatment decreases expression of ErbB2 (Read et al., 1990; Antoniotti et al., 1992; Russell and Hung, 1992; Taverna et al., 1994) , and increased expression of ErbB2 can abrogate the effect of antiestrogens and chemotherapy (Benz et al., 1993; Liu et al., 1995) . However, the high expression of ErbB2 alone is not a major factor in determining drug resistance in breast cancer cells. Coexpression of either EGFR or ErbB3 with ErbB2 significantly enhanced drug resistance (Chen et al., 2000) . The relation between ER and HRG expression is similarly unclear and controversial. One in vitro study showed that transfection of MCF-7 cells with HRG-b2 resulted in disruption of ER function and development of estrogen independence , and a clinical study reported that a higher percentage of ER-negative tumors expressed HRG compared with ER-positive tumors (Normanno et al., 1995) . Signaling through HRG-b2 results in suppression of ER signaling pathway (Grunt et al., 1995; Saceda et al., 1996; Tang et al., 1996) in contrast to activation of the same pathway by HRG-b1 (Pietras et al., 1995) . These differences could be because of either different concentrations of HRG expression in the MCF-7 cell lines used (complete inactivation of ER transcription was only observed in clones expressing high levels of HRG-b2) or to the HRG concentration used when treating MCF-7 cells (lower concentrations (10 À13 m HRG-b2) versus higher concentrations (10 À8 m HRG-b1)).
Recent data from this laboratory have demonstrated that epidermal growth factor (EGF) and insulin-like growth factor-I (IGF-I) regulate the expression and activity of ER-a by activating PI 3-K in the hormonedependent breast cancer cell line, MCF-7 (Stoica et al., 2000a, b) . One of the downstream targets of PI 3-K is Akt, a member of a conserved family of kinases, which includes AKT1/RAC-a, AKT2/RAC-b, and AKT3/ RAC-g in humans (Cheng et al., 1992) . AKT1 is amplified in gastric adenocarcinoma (Cheng et al., 1992) and is overexpressed in cancer cell lines, including MCF-7 (Miwa et al., 1996) . AKT2 is amplified in 12% of ovarian cancers (Bellacosa et al., 1995) , 10% of pancreatic cancers (Burgering and Coffer, 1995; Nakatani et al., 1999) , and 3% of breast carcinomas (Alessi et al., 1996) . AKT3 expression and activity is elevated in ER-negative breast cancer cells and is associated with more aggressive forms of breast tumors (Andjelkovic et al., 1997) . Akt is downstream of many growth factor signaling cascades (Franke et al., 1995; Andjelkovic et al., 1997) , including HRG (Carraway et al., 1995; Sepp-Lorenzino et al., 1996; Liu et al., 1999) . Akt contains a pleckstrin homology (PH) domain in its amino-terminal region, a kinase domain in the middle, and a regulatory domain in the carboxy-terminal region (Konishi et al., 1995) . The binding of phosphoinositides to the PH domain of Akt recruits Akt to the plasma membrane, where it is phosphorylated on threonine T308 and serine S473 (Klippel et al., 1996) . Activation of the Akt pathway results in cellular proliferative, as well as antiapoptotic cell responses (Downward, 1995; Cheng et al., 1997; Hemmings, 1997) . HRG may utilize the PI 3-K/Akt pathway to activate ER-a and confer hormone-independent growth. Apart from growth factors, estrogen also activates Akt in vascular endothelial cells (Marquez and Pietras, 2001 ) and in breast cancer cells (Stevis et al., 1999; Stoica et al., 2003a) . ERa, but not ER-b, can bind in a ligand-dependent manner to the regulatory subunit of PI 3-K in human vascular endothelial cells and in fibroblasts transfected with ER-a. Stimulation with physiological concentrations of estradiol increases ER-a-associated PI 3-K activity, leading to the activation of Akt and endothelial nitric oxide synthase (Watters et al., 1997) . These data suggest that PI 3-K is recruited and activated by a small subset of ligand-bound membrane-associated ERs. The PI 3-K signaling cascade is also involved in the neuroprotective mechanism stimulated by estradiol in rat primary cortical neurons (Honda et al., 2000) .
Previously, we have demonstrated that the two mitogenic growth factors EGF and IGF-I can regulate ER-a gene expression and activity via Akt (Martin et al., 2000) . In this paper, we now show that HRG-b1 can also rapidly activate Akt, and that Akt can modulate ER-a expression and activity following HRG-b1 treatment. Inhibitors of PI 3-K and a dominant-negative Akt or the R25C-Akt mutant inhibit the effect of HRG-b1 on ER-a expression and activity, whereas a constitutively active Akt mutant mimics the effect of HRG-b1. Selective inhibitor experiments demonstrate that the effect of HRG-b1 on Akt kinase activity as well as on ER-a expression and activity is mediated by the ErbB2 receptor tyrosine kinase, suggesting that ErbB2 is the primary mediator of the effects of HRG-b1 on ER-a regulation.
Results

HRG-b1 signal transduction is mediated by Akt
Previous results from this laboratory demonstrate that the PI 3-K/Akt pathway mediates the effects of EGF and IGF-I on the amount and activity of ER-a in the breast cancer cell line, MCF-7 (Martin et al., 2000; Stoica et al., 2000a, b) . To determine whether Akt is also a mediator of the HRG-b1 pathway, the ability of HRG-b1 to activate Akt through PI 3-K was tested. In this study, MCF-7 cells were serum-starved for 24 h and treated with several concentrations of HRG-b1 (10 À12 -10 À8 m) for 10 min or with 10 À9 m HRG-b1 for the times indicated (Figure 1 ). Western blot analysis was performed using an antibody that specifically recognizes Akt phosphorylated on S473. The cells were lysed and the amount of total and phosphorylated Akt was measured on immunoblots. The concentration dependence of Akt phosphorylation by HRG-b1 is presented in Figure 1a . Concentrations of HRG-b1 (10 À12 -10 À8 m) induced Akt phosphorylation with a maximum increase at 10
À9
-10
À8 m (15-16-fold increase). The time course of the activation of Akt by 10 À9 m HRG-b1 is presented in Figure 1b . HRG-b1 induced Akt activity very rapidly, with a maximum increase in 6 min that remained sustained for 1 h.
To determine whether the effect of HRG-b1 on Akt is mediated by PI 3-K, MCF-7 cells were serum-starved for 24 h and treated for 10 min with 10 À9 m HRG-b1 in the presence or absence of the PI 3-K inhibitors wortmannin (10 À7 m) or LY 294,002 (10 À5 m) ( Figure  2a, b) . Wortmannin and LY 294,002 blocked the effect of HRG-b1 on Akt phosphorylation providing evidence that activation of Akt is mediated by PI 3-K.
To determine whether the phosphorylation of Akt by HRG-b1 requires ER-a, serum-starved MCF-7 cells were treated for 10 min with 10 À9 m HRG-b1 in the presence or absence of two antiestrogens (5 Â 10 À7 m ICI 182,780 and 4-hydroxytamoxifen) (Figure 2a, b) . Phosphorylation of Akt by HRG-b1 was blocked by both ICI 182,780 and 4-hydroxytamoxifen. To further demonstrate the role of ER-a on Akt phosphorylation by HRG-b1, cotransfection experiments of wild-type ER-a into an ER-negative variant of MCF-7 cells, MCF-7/ADR, were performed ( Figure 2d ). The presence of transiently transfected ER-a was confirmed by Western blot analysis. In serum-starved MCF-7/ADR cells, HRG-b1 was not capable of inducing Akt phosphorylation (Figure 2c ). However, transient transfection of wild-type ER-a into these cells could restore the effect of HRG-b1 on Akt phosphorylation (Figure 2d ), suggesting that HRG-b1 phosphorylation of Akt requires ER-a. Heregulin-b1 activates ER-a via ErbB2/Akt GE Stoica et al To determine the mechanism of phosphorylation of Akt by HRG-b1, we used MCF-7 cells transfected with anti-ErbB2-targeted ribozymes, expressed under the control of a tetracycline-regulated promoter system (605+/À). The efficacy of this ribozyme was tested at the level of mRNA and protein. Stably transfected cells were grown in the absence or presence of tetracycline and ErbB2 mRNA levels were quantified by Northern blot analysis (Figure 2f ). ErbB2-targeted pTET/Rz605 expression depleted endogenous ErbB2 mRNA levels by 75% compared with control cells. Ribozyme-mediated depletion of ErbB2 protein expression was assessed by FACS analysis. Cell-surface expression of the ErbB2 protein was also suppressed by 75% when cells were grown in the absence of tetracycline (Figure 2f ), correlating very well with the results from the Northern blot analysis. Estradiol, EGF, and HRG-b1 did not activate Akt in the serum-starved cells with the ribozymes on (605À) ( Figure 2e ). As expected, in the serum-starved cells with the ribozymes off (605+), HRG-b1 phosphorylated Akt (Figure 2e) . Moreover, the effect of HRG-b1 on Akt activity was tested in the presence of genistein, a protein kinase inhibitor and with selective ErbB inhibitors (Figure 2a, b) . Genistein and AG825, a selective ErbB2 inhibitor, blocked HRG-b1 phosphorylation of Akt. However, the effect of HRG-b1 was not inhibited by the selective EGFR inhibitor, AG30, suggesting that ErbB2 but not EGFR is needed for the activation of Akt by HRG-b1. The effect of EGF, however, was blocked by the selective EGFR inhibitor, suggesting that EGFR is needed for the effect of EGF (Figure 2b ). To determine which Akt isoform was phosphorylated by HRG-b1, Western blot analyses were performed using anti-AKT1, AKT2, and AKT3 antibodies ( Figure 2e and data not shown). Since only AKT1 was expressed in our MCF-7 cells, we conclude that HRGb1 activates the AKT1 isoform.
PI 3-K and ErbB2 inhibitors can block HRG-b1-induced ER-a gene expression and activity HRG-b1 has been shown to modulate ER-a gene expression and activity (Pietras et al., 1995) . To determine whether PI 3-K inhibitors can block HRGb1-induced ER-a expression and/or activity, MCF-7 parental cells were treated with 10 À9 m HRG-b1 for 6 h in the presence or absence of 10 À7 m wortmannin or 10 À5 m LY 294,002. Estradiol served as a positive control. ER-a and progesterone receptor (PR) protein were measured using the enzyme immunoassay and RNase protection was performed to determine ER mRNA, PR mRNA, and pS2 mRNA (Figures 3 and 4). Estradiol (10 À9 m) decreased ER-a protein and mRNA by 75%; similarly, 10 À9 m HRG-b1 decreased ER-a protein and mRNA by 60%. This HRG-b1 effect was inhibited by wortmannin and LY 294,002 by 85 and 90% (Po0.005), respectively ( Figure 3 ). HRG-b1 induced PR protein, mRNA, and pS2 mRNA by twofold (as compared to a threefold increase by estradiol) and this effect was inhibited by wortmannin and LY 294,002 by about 90% (Po0.005) (Figure 4a , b), suggesting a role for PI 3-K.
To test whether the effect of HRG-b1 on ER-a is mediated by ErbB receptors, the selective inhibitors for ErbB2 and EGFR, AG825, and AG30, respectively were also used to determine their effects on ER-a regulation by HRG-b1 (Figures 3 and 4) . The effect of HRG-b1 on ER-a and PR protein and on ER mRNA, PR mRNA, and pS2 mRNA was blocked by AG825, but not by AG30, suggesting a role for ErbB2, but not EGFR. As a positive control, AG30 blocked the effect of EGF on ER and PR protein as well as on ER mRNA, PR mRNA, and pS2 mRNA. These results demonstrate that ErbB2 is the primary mediator of the effects of HRG-b1 on ER-a gene expression and activity.
Regulation of ER-a gene expression by HRG-b1 is mediated by Akt
To determine whether Akt regulates ER-a gene expression upon HRG-b1 treatment, MCF-7 cells were stably transfected with a dominant-negative Akt, a constitutively active form of Akt, or the R25C-Akt mutant. R25C-Akt was used because a comparable mutation in the PH domain of Bruton's tyrosine kinase (Btk) results in X-linked immunodeficiency in CBA/N mice (Rawlings et al., 1993) . Furthermore, Franke et al. have shown that this mutation in Akt does not affect its kinase function, but NIH 3T3 cells cotransfected with this Akt mutant failed to respond to platelet-derived growth factor (Franke et al., 1995) . The expression vector alone was employed as a negative control. Four to six clones, as well as a pool of stably transfected clones, were selected and Akt activity was characterized (Figure 5a ). Clones containing the kinase-defective mutant, K179M, were designated as K1-K4 and the pooled population was identified as Kp. For the constitutively active mutant, myr-Akt, the clones were designated as *** *** *** *** *** *** *** *** ** ** Figure 3 PI 3-K and ErbB2 inhibitors can block HRG-b1-induced ER-a gene expression. MCF-7 cells were grown in IMEM with phenol red supplemented with 5% charcoal-stripped serum (CCS). At 80% confluence, the medium was changed to phenol red-free IMEM with 5% CCS. After 2 days, the medium was replaced with serum-free medium and cells were treated for 6 h with 10 À9 m estradiol, 100 ng/ml EGF, or 10 À9 m HRG-b1 in the presence or absence of the PI 3-K inhibitors wortmannin (10 À7 m) or LY 294,002 (10 À5 m), or the selective ErbB inhibitors AG30 and AG825 (10 À7 m). ER-a protein was measured using an enzyme immunoassay and ER mRNA was determined by an RNase protection assay as described in Materials and methods. Results are expressed as a percentage of control cells and represent the mean value of three experiments7s.d. Statistical differences were determined using the Student's t-test, *Po0.05; **Po0.02; ***Po0.0005 m1-m6 and the pooled population was identified as mp. Clones containing an arginine to cysteine mutation (R25C) in the PH domain of Akt were labeled R1-R5, and the pooled population was identified as Rp. In cells stably transfected with the dominant-negative Akt mutant or R25C-Akt, the ability of HRG-b1 to activate Akt was inhibited. In cells transfected with the constitutively active mutant, even in the absence of HRG-b1, the kinase was active as measured by the amount of phosphorylation of Akt on S473. MCF-7 cells transfected with the expression vector alone behaved similarly to the parental MCF-7 cell line (Martin et al., 2000) .
To demonstrate that the effect of HRG-b1 on ER-a expression was mediated by Akt, cells that were stably transfected with the Akt mutants were treated with HRG-b1 and its effect on ER-a protein and mRNA were measured. Prior to treatment with 10 À9 m HRG-b1, the cells were serum-starved for 24 h. The amounts of ER-a protein and mRNA were measured by an enzyme immunoassay and an RNase protection assay, respectively. Estradiol was used as a positive control. In the parental MCF-7 cells and in MCF-7 cells stably transfected with the empty vector, HRG-b1 treatment resulted in a 50-60% decrease in total receptor protein and ER-a mRNA, respectively (Figure 5b) . Expression of the kinase-inactive Akt mutant in clones K1, K2, and Kp, as well as the R25C-Akt mutant in clones R1, R5, and Rp did not alter ER-a expression, but blocked the effect of HRG-b1 on receptor protein and mRNA by 80-90% (Po0.005). In contrast, the overexpression of the constitutively active Akt mutant in clones m2, m4, m5, and mp mimicked the effect of HRG-b1 on receptor expression (Martin et al., 2000) . Addition of HRG-b1 did not further decrease ER protein and ER mRNA. These results suggest that the regulation of ER-a gene expression by HRG-b1 is mediated by Akt. In addition, Akt activates ER-a resulting in receptor downregulation, similar to the downregulation observed following receptor activation by estradiol and other growth factors (Saceda et al., 1988; Read et al., 1989; Berry et al., 1990; Garcia-Morales et al., 1994; Metzger et al., 1995) .
HRG-b1 activation of ER-a can be modulated by Akt
To determine whether Akt is involved in the steroidindependent activation of ER-a by HRG-b1, the ability of the dominant-negative Akt or the R25C-Akt and the constitutively active Akt mutant to either block or mimic the effect of HRG-b1 was investigated. The ability of the dominant-negative and the R25C-Akt mutants to block the effect of HRG-b1 was tested in the K1, K2, and Kp as well as in the R1, R5, and Rp clones. The amounts of progesterone receptor protein and mRNA were measured by an enzyme immunoassay MCF-7 cells were grown and treated as described in Figure 3 . PR protein, PR mRNA, and pS2 mRNA were measured by an enzyme immunoassay and an RNase protection assay, respectively. Results are expressed as a percentage control and represent the mean value of three experiments7s.d. Statistical differences were determined as described in Figure 3 Heregulin-b1 activates ER-a via ErbB2/Akt GE Stoica et al and an RNase protection assay, respectively. The results were compared to the parental MCF-7 cells (Figure 6 ). Estradiol was used as a positive control. In the parental MCF-7 cells, HRG-b1 induced progesterone receptor protein and mRNA by 2.5-3-fold, Po0.009. In MCF-7 cells stably transfected with the dominant-negative or the R25C-Akt mutants, the effect of HRG-b1 was significantly blocked. In MCF-7 cells stably transfected À9 m HRG-b1 for 10 min. Western blot analysis was performed using an antiphospho-Akt (S473) antibody. Representative immunoblots of three independent experiments. (b) Parental and stably transfected MCF-7 cells with K179M-Akt (clones K1, K2, and Kp), myr-Akt (clones m2, m4, m5, and mp) or with R25C-Akt (clones R1, R5, and Rp) were grown in IMEM supplemented with 5% CCS. At 80% confluence, the medium was changed to phenol red-free IMEM with 5% CCS. After 2 days, the medium was replaced with serum-free medium and the cells were treated for 6 h with 10 À9 m HRG-b1 or 10 À9 m estradiol. ER-a protein was measured using an enzyme immunoassay and ER-a mRNA was determined by an RNase protection assay. Results are expressed as a percentage control and represent the mean value of three experiments7s.d. Statistical differences were determined as described in Figure 3 Figure 6 Akt modulates ER-a activity. Parental and stably transfected MCF-7 cells with dominant-negative K179 M-Akt (clones K1, K2, and Kp), myr-Akt (clones m2, m4, m5, and mp) or with R25C-Akt mutants (clones R1, R5, and Rp) were grown and treated as described in the legend of Figure 5 . PR protein was measured using the enzyme immunoassay and PR mRNA was measured by an RNase protection assay. Results are expressed as a percentage of control and represent the mean value of three experiments7s.d. Statistical differences were determined as described in Figure 3 Heregulin-b1 activates ER-a via ErbB2/Akt GE Stoica et al with the constitutively active mutant, a 4-9-fold and a 2.5-7.5-fold increase in progesterone receptor protein and mRNA, respectively, was observed in the absence of treatment with HRG-b1 (Martin et al., 2000) . Addition of HRG-b1 did not further increase PR protein and PR mRNA. The expression vector alone did not alter the effect of HRG-b1 on ER-a activity, suggesting that HRG-b1 activation of ER-a is mediated by Akt.
% Control
HRG-b1 and Akt can influence the growth and tamoxifen resistance of MCF-7 cells
To determine whether HRG-b1 and Akt can also regulate cell growth, parental and MCF-7 cells stably transfected with the three Akt mutants were treated with 10 À9 m HRG-b1 in the presence or absence of the two antiestrogens 4-hydroxytamoxifen and ICI 182,780, and cell number was determined on days 2-8 ( Figure 7 , upper panels). In parental MCF-7 cells, as expected, 10 -9 m HRG-b1, like estradiol, stimulated the growth of cells when compared with cells grown in estrogendepleted medium (10.5-fold increase). Both antiestrogens could block the effect of HRG-b1. In MCF-7 cells stably transfected with constitutively active Akt (MCF-7/myr-Akt), even without HRG-b1 treatment, cells grew to a level that was comparable with the degree of growth stimulation induced by HRG-b1 in parental MCF-7 cells (ninefold increase). HRG-b1 produced a 15-fold increase in cell number in these cells as compared with the parental control cells. 4-Hydroxytamoxifen only partially inhibited the growth of MCF-7/myr-Akt cells and had a weak agonistic effect, producing an approximately threefold increase in cell number on day 8 after treatment. In contrast to 4-hydroxytamoxifen, cells were significantly growth inhibited by the pure antiestrogen ICI 182,780, which inhibits ER-a activity by preventing DNA binding and enhancing degradation (Dauvois et al., 1993) . These results suggest that HRG-b1 and Akt can present estrogen-like activity on cell growth and, in the presence of constitutively active Akt, MCF-7 cells Figure 7 HRG-b1 and Akt can modulate the growth of MCF-7 Cells. (a) Growth curves. MCF-7, MCF-7/myr-Akt, MCF-7/K179M-Akt, and MCF-7/R25C-Akt cells were plated in six-well plates at a density of 4 Â 10 5 cells/well and grown in IMEM with phenol red supplemented with 5% charcoal-stripped serum (CCS). At 80% confluence, the medium was changed to phenol red-free IMEM with 5% CCS. After 2 days, the medium was replaced with serum-free medium and cells were treated with 10 À9 m HRG-b1 in the presence or absence of tamoxifen or ICI 182,780 (5 Â 10 À7 m). Cells were counted at the times indicated. Results are expressed as percentage of control in the parental cell line and represent the mean value of three independent experiments performed in triplicate7s.d. (b) Cell cycle analysis. MCF-7, MCF-7/myr-Akt, MCF-7/K179M-Akt, and MCF-7/R25C-Akt cells were plated and grown as described in Materials and methods. After treatment for 3 days with 10 À9 m HRG-b1 in the presence or absence of tamoxifen, ICI 182,780 (5 Â 10-7 m), or 10 À9 m estradiol, cells were washed twice with phosphate-buffered saline, resuspended in 0.1 ml citrate/DMSO buffer, and cell cycle analysis was performed after Vindelov staining as described in Materials and methods. The values represent the mean of three independent assays7s.d.
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GE Stoica et al become estrogen-resistant towards tamoxifen. In stably transfected MCF-7 cells with dominant-negative Akt (MCF-7/K179M-Akt) or with R25C-Akt, however, the effect of HRG-b1 on cell growth were inhibited by 70% (Po0.05) and 50% (Po0.05), respectively, and both antiestrogens could block its effect. To further confirm the mitogenic effect of HRG-b1 and Akt on growth as well as the inhibitory effect of a dominant-negative Akt or the R25C-Akt mutant, cell cycle analysis was performed (Figure 7, lower panel) . After 3 days of treatment with 10 -9 m HRG-b1, the population of cells in the S+G2M phases of the cell cycle increased 4.2-fold in parental MCF-7 cells, similar to the increase produced by estradiol (2.7-fold increase). The effect of HRG-b1 was blocked by both antiestrogens in parental cells as well as in MCF-7 cells stably transfected with either K179M-Akt or R25C-Akt, suggesting the involvement of ER-a and Akt. In contrast, in MCF-7/myr-Akt cells, even in the absence of HRG-b1, the population of cells in the S+G2M phases of the cell cycle increased to 3.5-fold, effect which could be significantly inhibited by the total antiestrogen ICI 182,780. However, 4-hydroxytamoxifen had an agonistic effect in these cells, resulting in a 2.4-fold increase in these cells. When parental MCF-7 cells were treated with both estradiol and HRG-b1, an additive effect was observed (sixfold increase). Similarly, HRGb1 produced a further increase over control values in MCF-7/myr-Akt cells (fivefold increase).
Discussion
A great body of evidence has accumulated demonstrating that growth factors can activate the ER in the absence of estradiol. However, the signal transduction pathways involved in their activation are poorly understood. This paper provides evidence that HRG-b1 can modulate ER-a, and the crosstalk between the HRG-b1 and the estrogen signal transduction pathways is mediated by the ErbB2/PI 3-K/Akt pathway in the ER-positive cell line, MCF-7. Treatment of cells with 10 À9 m HRG-b1 decreased ER-a protein and mRNA concentrations and increased ER-a activity as measured by an induction in the estrogen-regulated genes, progesterone receptor and pS2. Similar to estradiol, EGF, and IGF-I, HRG-b1 increased cell growth. HRGs have previously been reported to promote growth, induce differentiation, and inhibit proliferation depending on the concentration and cell lines examined . Low concentrations of HRGs (HRG-b1 or HRG-b2) (2.5 Â 10 À15 -9 Â 10 À12 m) inhibited ER-a activity (Grunt et al., 1995) and binding to its response element in a DNA mobility shift assay (Saceda et al., 1996) , as well as estradiol-induced growth of breast cancer cell lines . In contrast, higher concentrations of HRGs (10 À9 -10 À8 m) produced an increase in growth of MCF-7 and T47D cells (Aguilar et al., 1999; Lichtner et al., 1999; Angus et al., 2000) and activated ER-a (Pietras et al., 1995) . The difference between the effects of high and low concentrations was previously observed by us for another member of the ErbB family, EGF (Stoica et al., 2000a) . Similar to HRGs, high concentrations of EGF activated ER-a (Ignar-Trowbridge et al., 1993; El-Tanani and Green, 1997a; Kato, 2001 ) while low concentrations of EGF inhibited ER-a activity (Stoica et al., 2000a) . These differences may be because of the activation of different members of the ErbB receptor family by different concentrations of ligand, leading to activation of alternate signaling pathways.
Activation of the PI 3-K/Akt pathway appears to be an essential step in the estrogenic action of EGF and IGF-I in MCF-7 cells (Martin et al., 2000; Stoica et al., 2000a, b) . Here, we show that HRG-b1 can also activate PI 3-K/Akt, and that its effect is mediated by ErbB2 and ER-a. Although evidence exists for the activation of Akt by HRG-b1 in MCF-7 or T47D cells (Angus et al., 2000) , this is the first report that links activation of Akt by HRG-b1 to modulation of ER-a. Moreover, we report a new molecular mechanism of modulation of ER-a by HRG-b1 in which ErbB2 is the primary mediator of the effects of HRG-b1 on ER-a regulation (Figure 8 ). Using MCF-7 cells stably transfected with anti-ErbB2-targeted ribozymes and selective ErbB inhibitors, we demonstrate that ErbB2 and not EGFR is required for Akt activation by HRGb1. In addition, using the antiestrogens 4-hydroxytamoxifen and ICI 182,780 and the ER-negative variant of MCF-7 cells, MCF-7/ADR, we show that ER-a is also required for the HRG-b1 effect. Since MCF-7 cells overexpress ErbB3, but not ErbB4 (Wosikowski et al., 1997) and HRG-b1 exhibits high-affinity binding to the heterodimer ErbB2 ErbB3, resulting in the phosphorylation of ErbB2 (Holmes et al., 1992; Sliwkowski et al., 1994) , we expect that HRG-b1 may activate the ErbB2 ErbB3 heterodimer, coupled with membrane ER. Activated ErbB3 may recruit and activate PI 3-K via phosphorylation of YXXM motifs in the ErbB3 carboxy-terminal domain Prigent and Gullick, 1994; Soltoff et al., 1994; Carraway et al., 1995) . Activated PI 3-K in turn may lead to Akt activation. Akt may phosphorylate nuclear ER-a on serines S104, S106, S118, and/or S167 in the AF-1 domain of ER-a (Martin et al., 2000; Campbell et al., 2001) , leading to alterations in its gene transcription and activity. We have previously demonstrated that, similar to HRG-b1, estradiol bound to membrane ER can rapidly activate the same ErbB2/PI 3-K/Akt pathway in MCF-7 cells, providing an additional evidence for crosstalk between the ER-a and the HRG signaling pathways (Stoica et al., 2002a) . This estrogenic effect is a specific nongenomic effect. More and more evidence argues for the existence of another ER or an isoform of ER that is associated with the membrane. It is not known how the ER interpolates with the membrane and how it couples to intracellular signaling cascades. In one model, ER spans the membrane and its post-translational lipid modification in the endoplasmic reticulum may facilitate its movement from the nucleus/cytoplasm to the membrane (Improta-Brears et al., 1999) . A second, more compelling model, is that, at least for a certain time, the ER exists entirely within the membrane (Schnitzer et al., 1995; Mermelstein et al., 1996) in the low-density membrane vesicles, called caveoli (Kim et al., 1999) . Growth factor receptors also localize to the caveoli, where downstream signaling, such as Ras, Src, and PI 3-K may be facilitated (Okamoto et al., 1998) . Several questions regarding the nature of the interaction between the membrane ER and ErbB2 remain still open. Previously, a physical and functional interaction of estrogens and the ErbB2 protein was demonstrated (Matsuda et al., 1993) . Estrogen and a putative ligand(s) of ErbB2 might recognize a common region of ErbB2 and compete for binding to the receptor due to the significant homology (B36%) of the ErbB2 extracellular domain with that of the ligand-binding domain of ER (residues 449-568) (Matsuda et al., 1993) . More recently, it has been shown that estradiol induced an increase in ErbB2 phosphorylation, but had little effect on EGFR phosphorylation when MCF-7 cell lysates stably transfected with either anti-ErbB2 or anti-EGFR were immunoprecipitated with either ErbB2 or EGFR antibody, respectively, and probed with antiphospho-tyrosine antibody (Keshamouni et al., 2002) . Additionally, a physical association between cell membrane ER-a and ErbB2 was reported in BT474 and MCF-7 cells by co-immunoprecipitation of ER-a by the anti-ErbB2 antibody and by detection of ErbB2 by the reciprocal coimmunoprecipitation using the anti-ER-a antibody (Chung et al., 2002) .
We have previously shown that the activation of the PI 3-K/Akt pathway leads to tamoxifen resistance in breast cancer cells, and that overexpression of Akt results in an increase in cell growth and in the population of cells in the S+G2M phases of the cell cycle (Stoica et al., 2002b) . This effect could not be blocked by 4-hydroxytamoxifen and was only partially blocked by the total antagonist ICI 182,780. Similar to the effect of estradiol, HRG-b1 could produce an increase in cell number as measured by an anchoragedependent growth assay and in the population of MCF-7 cells in the S+G2M phases of the cell cycle as measured by a cell cycle analysis. However, in MCF-7/ ADR cells, no effect of HRG-b1 on cell growth was observed (data not shown). The effect of HRG-b1 on cell growth in MCF-7 cells could significantly be inhibited by either a dominant-negative or by the R25C-Akt. Transfection of ErbB2 cDNA or HRG-b2 cDNA into MCF-7 cells was also shown to result in development of estrogen-independent growth in vitro (Pietras et al., 1995) or in vivo . Treatment with a combination of tamoxifen and an ErbB2 kinase inhibitor markedly prevented the growth of ErbB2-overexpressing MCF-7 xenografts in athymic mice (Kurokawa et al., 2000) and overexpression of ErbB2 in breast cancer cells was shown to lead to Akt activation Zhou et al., 2000) . ERpositive tumor-derived cell lines are known to express relative low levels of ErbB2 protein under estrogenic conditions, but markedly higher levels following withdrawal of estrogens or administration of antiestrogens (Pietras et al., 1995) . DNase I footprinting revealed an enhancer element in the first intron of the ErbB2 promoter that mediates estrogen-induced suppression of ErbB2 overexpression. Additionally, there is likely to Figure 8 Molecular mechanism of modulation of ER-a by HRG-b1 via ErbB2/PI 3-K/Akt. HRG-b1, bound to ErbB3 and in the presence of membrane ER-a activates the ErbB2 ErbB3 heterodimer. Activated ErbB3 may recruit and activate PI 3-K via phosphorylation of YXXM motifs in the ErbB3 carboxy-terminal domain. Activated PI 3-K, in turn, may lead to Akt activation. Akt may phosphorylate nuclear ER-a on serines S104, S106, S118, and/or S167 in the AF-1 domain of ER-a, leading to alterations in its gene transcription and activity Heregulin-b1 activates ER-a via ErbB2/Akt GE Stoica et al exist synergism between ErbB2 and ErbB3 signaling when both are overexpressed in response to estrogen inhibition, thereby amplifying the cell transforming behavior (Bates and Hurst, 1997 Yoo et al., 1998; Brockhoff et al., 2001 ), AU-565, MDA-MB231 (Yoo et al., 1998) , and LM3 (Puricelli et al., 2002) . The MAPK pathway is also thought to play an important role in mediating the effect of HRG-b1 on cell proliferation and activation of ER-a. Although the signaling mechanism(s) responsible for MAPK activation are not fully characterized, HRG-b1 can induce activation of Erk in MCF-7 breast cancer cells, similar to Akt activation (Tan et al., 1999) and inhibition of MAPK with a selective inhibitor or a dominant-negative construct can restore the inhibitory effect of tamoxifen on ER-mediated transcription and cell proliferation (Kurokawa et al., 2000) . In contrast to this rapid effect of HRG-b1, more recently, a slow but sustained estradiol activation of Erk up to 24 h was also demonstrated and this effect is mediated by secretion of HRG and activation of ErbB2 by an autocrine/ paracrine mechanism additionally involving the PKCd and the Ras pathway (Keshamouni et al., 2002) . The ability of both the PI 3-K and MAPK/Erk pathways to affect ER-a function suggests that ER is a point of convergence of the Akt and MAPK pathways. It is not clear yet whether the Akt and MAPK pathways are alternate pathways or whether they crosstalk with each other. There have been reports demonstrating that Akt is preferred to Erk in HRG-induced cell processes in breast cancer cells, such as mitogenesis, cell cycle progression (Daly, 1999) , and aggregation (Tan et al., 1999) . It appears that both MAPK and Akt pathways are often activated simultaneously with apparently conflicting responses such as apoptosis, growth arrest, differentiation, and senescence, depending on the cell type, duration, and strength of the stimulus (Rommel et al., 1999) . Also, activation of different receptor tyrosine kinases or activation of the same receptor tyrosine kinase with different ligands can lead to distinct profiles of gene regulation within a single cell type. The identity and kinetics of signaling pathway usage by receptor tyrosine kinases may play a role in the selection of the regulated genes (Sweeney et al., 2001) .
In this paper, we report that HRG-b1, at nanomolar concentrations, can increase cell proliferation and can modulate ER-a gene expression and activity, mediated by the ErbB2/PI 3-K/Akt pathway. Similar to HRG-b1, we have previously reported that estradiol, EGF, and IGF-I can also modulate cell proliferation and ER-a gene expression and activity via the same PI 3-K/Akt pathway (Martin et al., 2000; Stoica et al., 2002a, b) . Moreover, estradiol seems to mimic HRG-b1 since ErbB2 but not EGFR is required for its effect on Akt activity (Stoica et al., 2002a) . Our results show that the nongenomic and genomic effects of estradiol are coupled and converge in the ErbB2/PI 3-K/Akt pathway. Besides the insights into novel interactions between ER-a and growth factor signaling cascades, these results may lead to new prognostic and/or therapeutic targets. Interruption of the ErbB2 and/or Akt signal transduction may enhance the inhibitory effect of antiestrogens on both ER-a mediated transcription and on tumor cell proliferation.
Materials and methods
Cell culture
Monolayer cultures of MCF-7 cells were grown in improved minimal essential medium (IMEM), supplemented with 5% fetal calf serum (FCS). At 80% confluence, the medium was replaced with phenol red-free IMEM containing 5% charcoaltreated calf serum (CCS) (Berthois et al., 1986) . The calf serum was pretreated with sulfatase and dextran-coated charcoal to remove endogenous steroids (Saceda et al., 1988) . After 2 days, the medium was changed into serum-free, phenol red-free IMEM supplemented with fibronectin, glutamine, HEPES, trace elements, and transferrin, after which 10 À9 m estradiol, 100 ng/ml EGF, or 10 À9 m HRG-b1 were added. Cells were harvested at the times indicated. MCF-7/ADR cells were initially obtained from the tumor bank of the National Cancer Institute (Bethesda, MD, USA) (Mimnaugh et al., 1991) and were cultured as the ER-positive MCF-7 cells.
Epidermal growth factor was purchased from Upstate Biotechnology, Lake Placid, NY, USA; HRG-b1 was obtained from R&D Systems Inc., Minneapolis, MN, USA; 17b-estradiol, 4-hydroxytamoxifen (Tam), and wortmannin were purchased from Sigma, St Louis, MO, USA. Genistein, the selective ErbB receptor inhibitors AG 30 (for EGFR) and AG 825 (for ErbB2), and LY 294,002 were purchased from Calbiochem, San Diego, CA, USA.
Plasmids
The clone 36B4 was constructed by subcloning a 220-bp fragment of 36B4 into the PstI restriction site of the pGem polylinker (Saceda et al., 1988) . The clones for pS2 (GarciaMorales et al., 1994) , glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (McLeskey et al., 1993) , and progesterone receptor (PR) (Stoica et al., 1997) were used as previously described.
The expression vector for Akt (HA-Akt) (Franke et al., 1995) , the kinase defective Akt (HA-Akt (K179M)), the constitutively active Akt (myrAkt-HA) (Ahmed et al., 1993) , and the Akt mutant carrying an arginine to cysteine mutation at amino acid 25 (R25C-Akt) (Franke et al., 1995) were generated as HindIII-BamHI inserts in pCMV-6. The expression vector for ER-a (HEG0) was described elsewhere (Metzger et al., 1995) .
Measurement of PR mRNA, pS2 mRNA, and ErbB2 mRNA Total cellular RNA was extracted from MCF-7 cells by the RNazol method. The amounts of PR, pS2, 36B4, and GAPDH were determined by an RNase protection assay (Saceda et al., 1988) . Briefly, homogeneously 32 P-labeled antisense cRNA were synthesized in vitro from pS2, 36B4, and pGAPDH using T7 polymerase and from PR using SP6 polymerase. Total RNA (60 mg) were hybridized for 12-16 h to the radiolabeled cRNA. After a 30 min digestion at 251C with RNase A, 32 Plabeled cRNA probes protected by total RNA were separated by electrophoresis on 6% polyacrylamide gels. The bands were visualized by autoradiography and quantified using a phosphor imager. The amounts of pS2 mRNA and PR mRNA were normalized to the internal control 36B4 and GAPDH, respectively.
ErbB2 mRNA and GAPDH mRNA were determined by Northern blot analysis. Total RNA (30 mg) from MCF-7 cells stably expressing an anti-ErbB2 targeted ribozyme under the control of a tetracycline-regulated promoter, was analysed for ErbB2 expression in the presence (ribozyme-off) or absence (ribozyme-on) of tetracycline (1 mg/ml). ErbB2 mRNA was quantified relative to GAPDH mRNA by densitometry.
Western blot analysis
MCF-7 cells (parental, stably transfected with a dominantnegative Akt mutant (Martin et al., 2000) , an arginine to cysteine mutant at the amino acid 25 in the PH domain of Akt (R25C), or with an anti-ErbB2-targeted ribozyme (Juhl et al., 1997) ) were preincubated for 20 min with the inhibitors of PI 3-K, wortmannin (10 À7 m) and LY 294,002 (10 À5 m), genistein (10 À7 m), a protein tyrosine kinase inhibitor, or the selective inhibitors for ErbB AG 30 and AG 825 (10 À7 m) and treated with estradiol (10 À9 m), EGF (100 ng/ml), or HRG-b1 (10 À9 m) for 10 min. Cells were lysed in NP-40 lyses buffer; the lysates were heated to 95-1001C for 5 min and equal amounts of protein (100 mg) were loaded onto SDS polyacrylamide gels. Gels were electrotransferred to PVDF membranes, washed in phosphate-buffered saline five times at room temperature. Membranes were kept in blocking buffer overnight at 41C and incubated with the primary antibody (either antiphospho-Akt antibody (Ser 473) or anti-Akt antibody (New England Biolabs, Beverly, MA, USA)) for 1 h at room temperature. After three additional washes in phosphate-buffered saline, membranes were incubated with the horseradish peroxidaseconjugated secondary antibody (1 : 2000) in blocking buffer for 1 h at room temperature. Detection was performed by chemiluminescence, using Super Signal chemiluminescent substrate (Pierce, Rockford, IL, USA) .
MCF-7/ADR cells (parental and transiently transfected with the ER-a expression vector, HEG0) were treated with or without 10 À9 m HRG-b1 for 10 min. Cells were lysed in RIPA buffer with freshly added inhibitors, the lysates were heated to 951C for 5 min and equal amounts (60 mg) were loaded onto SDS polyacrylamide gels. Gels were electrotransferred to PVDF membranes, washed in phosphate-buffered saline five times at room temperature. Membranes were kept in blocking buffer overnight at 41C and incubated for 1 h at room temperature with an anti-ER-a primary antibody (HC-20, Santa Cruz Biotechnology, Santa Cruz, CA, USA) (1 : 1000). After three additional washes in phosphate-buffered saline, membranes were incubated for 45 min at room temperature with the horseradish peroxidase-conjugated secondary antibody (1 : 500) in blocking buffer. Detection was performed by chemiluminescence, using Super Signal chemiluminescent substrate (Pierce, Rockford, IL, USA) .
Transfections
Stable transfection of MCF-7 cells (passage 47) with a constitutively active Akt (myr-Akt), a dominant-negative Akt (K179M-Akt), and an arginine to cysteine Akt mutant at amino acid 25 in the PH domain (R25C-Akt) was performed with lipofectamine Plus (Gibco/BRL, Rockville, MD, USA) according to the manufacturer's instructions and is described elsewhere (Martin et al., 2000) . Transfected cells were selected in IMEM supplemented with 10% FCS and 500 mg/ml G418 for about 1 month. Single colonies as well as pools of transfected colonies were picked up, serum starved, and treated with 10 À9 m estradiol and enzymatic activity of Akt was tested. Stable transfection of MCF-7 cells with antiErbB2-targeted ribozymes is described in detail elsewhere (Juhl et al., 1997) .
Transient transfection of ER-a (HEG0) (Metzger et al., 1995) into MCF-7/ADR cells was also performed with lipofectamine Plus (Gibco/BRL, Rockville, MD, USA). Briefly, 10 6 cells were plated into 100 mm dishes and transfected with 5 mg of HEG0. After 16-18 h, cells were washed and serum-free medium was added. After 1 day, transfected cells were treated with 10 À9 m HRG-b1 for 10 min and cell lysates were used for Western blot analysis for Akt activity and expression and for ER-a expression.
Anchorage-dependent growth assays
MCF-7 cells (parental or stably transfected with myr-Akt, K179M-Akt, or R25C-Akt) were plated at 10 5 cells/well into six-well plates in IMEM supplemented with 5% FCS. Cells were grown to 40% confluence and the medium was changed to phenol red-free IMEM supplemented with 5% CCS. After 2 days the medium was replaced with serum-free medium and cells were treated with 10 À9 m HRG-b1 in the presence or absence of the antiestrogens ICI 182, 780, tamoxifen (5 Â 10 À7 m), or 10 À9 m estradiol. Medium with the appropriate treatments was replaced every 3 days. Cells were trypsinized at the specific time points and counted with a coulter counter (Coulter Electronics, Inc., Hialeah, FL, USA).
Cell cycle phase analysis
For cell cycle analysis, MCF-7 cells (parental, or stably transfected with the Akt mutants: myr-Akt, K179M-Akt, or R25C-Akt) were grown as described above and treated for 3 days with 10 À9 m HRG-b1 in the presence or absence of the antiestrogens ICI 182,780, hydroxytamoxifen (5 Â 10 À7 m), or 10 À9 m estradiol. The cells were trypsinized to obtain a single cell suspension and verified microscopically after neutralizing with medium containing serum. The cell number was adjusted to 2 Â 10 6 cells for each treatment. The cells were washed twice with phosphate-buffered saline, centrifuged at 1000 r.p.m. for 5 min and suspended in a 0.1 ml citrate/dimethylsulfoxide buffer. The DNA content was measured by Vindelov staining (55). Briefly, 900 ml of solution A (15 mg trypsin in 500 ml stock solution: trisodium citrate, NP-40, spermidine tetrahydrochloride, Tris, pH 7.6) were added to the cell suspension in citrate buffer, vortexed, and incubated at room temperature for 10 min. A volume of 750 ml solution B (250 mg trypsin inhibitor and 50 mg ribonuclease A in 500 ml stock solution, pH 7.6) was added to the tubes, mixed by vortexing lightly, and incubated at room temperature for 10 min. Then, 750 ml ice-cold solution C (208 mg propidium iodide and 580 mg spermidine tetrahydrochloride in 500 ml stock solution, pH 7.6) was added to the samples. The solutions were mixed and filtered through a 37 mm nylon mesh into tubes wrapped in tinfoil for light protection in a covered ice bucket. Samples were run in the flow cytometer between 15 min and 3 h after addition of solution C.
Fluorescence-activated cell sorting (FACS)
To quantify ErbB2 protein levels by FACS analysis, cells were trypsinized, washed once with growth medium containing serum and twice with phosphate-buffered saline and resuspended in phosphate-buffered saline at 5 Â 10 5 cells/100 ml. Cells were incubated for 30 min at 41C with a 1 : 100 dilution of a primary anti-human ErbB2 mouse monoclonal antibody (clone 9G6.10; Neomarkers, Fremont, CA, USA). Cells were washed twice with phosphate-buffered saline and incubated for 30 min at 41C in the dark with a 1 : 200 dilution of a fluorescein isothiocyanate-labeled goat anti-mouse secondary antibody (Boehringer Mannheim). After two final washes in phosphatebuffered saline, the mean value of fluorescence intensity of 10 000 cells was determined by FACS (FACStar Plus, Becton Dickinson). Unlabeled cells and cells labeled with secondary antibody alone served as negative controls.
